The recently created dual agonists for PPARα/γ, G4 and G5, reduce known side effects while improving systemic glucose metabolism, hyperlipidemia, and markers of liver injury in rats with insulin resistance induced by a high-fructose diet108. This evidence concerns the gene PPARA and Insulin resistance.